Latest news with #Fujisawa
Yahoo
24-06-2025
- Business
- Yahoo
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
FUJISAWA, Japan & BOSTON, June 24, 2025--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds developed by Superluminal using its unique predict-design-test architecture. In addition, the two companies collaborated on predictive ADME modeling, resulting in models that both companies can use as needed for their respective business purposes. Building on this foundation, the new project will combine Axcelead DDP's comprehensive drug discovery platform, including its pharma-originated research data, rich experienced medicinal chemistry, and in vitro/in vivo pharmacology, with Superluminal's cutting-edge computational, AI/ML, and structure-based drug design capabilities. The collaboration aims to accelerate the discovery and development of innovative small-molecule therapeutics by jointly addressing multiple defined molecular targets with high unmet medical needs. "At Axcelead DDP, we have advanced our drug discovery platform, originally inherited from a top-tier pharmaceutical company, mainly through our own research, while strategically collaborating with external partners," said Kengo Okada, Ph.D., Representative Director and CEO of Axcelead DDP. "By applying this platform to support and accelerate Superluminal's drug discovery efforts targeting multiple mechanisms, we aim to contribute to the advancement of their pipeline and help address areas of high therapeutic demand. Our vision is to remain the drug discovery solution provider of choice for a diverse range of innovation-driven partners." Cony D'Cruz, CEO of Superluminal, added, "We are pleased with our partnership with Axcelead DDP. We appreciate the deep pharma experience and broad range of capabilities that enable Axcelead DDP to provide comprehensive drug discovery support to companies such as Superluminal." About Axcelead DDP Axcelead DDP is Japan's first drug discovery solution provider, established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions with original compound library and large drug discovery database are integrated into one center with a state-of-the-art research base. Together with experienced drug discovery scientists, Axcelead DDP creates high-quality drug candidates rapidly. By leveraging these strengths, Axcelead DDP provides solutions to various challenges faced in the process, from exploratory research to clinical trials in drug discovery. For more information, please visit About Superluminal Superluminal's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company's proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors, including RA Capital, Insight Partners, NVIDIA, Catalio Capital, Eli Lilly and Company, and Gaingels. For more, visit View source version on Contacts Axcelead Drug Discovery Partners, Superluminal Medicines, McCargo 6 Degreesjmccargo@ Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
FUJISAWA, Japan & BOSTON, June 24, 2025--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds developed by Superluminal using its unique predict-design-test architecture. In addition, the two companies collaborated on predictive ADME modeling, resulting in models that both companies can use as needed for their respective business purposes. Building on this foundation, the new project will combine Axcelead DDP's comprehensive drug discovery platform, including its pharma-originated research data, rich experienced medicinal chemistry, and in vitro/in vivo pharmacology, with Superluminal's cutting-edge computational, AI/ML, and structure-based drug design capabilities. The collaboration aims to accelerate the discovery and development of innovative small-molecule therapeutics by jointly addressing multiple defined molecular targets with high unmet medical needs. "At Axcelead DDP, we have advanced our drug discovery platform, originally inherited from a top-tier pharmaceutical company, mainly through our own research, while strategically collaborating with external partners," said Kengo Okada, Ph.D., Representative Director and CEO of Axcelead DDP. "By applying this platform to support and accelerate Superluminal's drug discovery efforts targeting multiple mechanisms, we aim to contribute to the advancement of their pipeline and help address areas of high therapeutic demand. Our vision is to remain the drug discovery solution provider of choice for a diverse range of innovation-driven partners." Cony D'Cruz, CEO of Superluminal, added, "We are pleased with our partnership with Axcelead DDP. We appreciate the deep pharma experience and broad range of capabilities that enable Axcelead DDP to provide comprehensive drug discovery support to companies such as Superluminal." About Axcelead DDP Axcelead DDP is Japan's first drug discovery solution provider, established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions with original compound library and large drug discovery database are integrated into one center with a state-of-the-art research base. Together with experienced drug discovery scientists, Axcelead DDP creates high-quality drug candidates rapidly. By leveraging these strengths, Axcelead DDP provides solutions to various challenges faced in the process, from exploratory research to clinical trials in drug discovery. For more information, please visit About Superluminal Superluminal's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company's proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors, including RA Capital, Insight Partners, NVIDIA, Catalio Capital, Eli Lilly and Company, and Gaingels. For more, visit View source version on Contacts Axcelead Drug Discovery Partners, Superluminal Medicines, McCargo 6 Degreesjmccargo@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
FUJISAWA, Japan & BOSTON, June 24, 2025--(BUSINESS WIRE)--Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds developed by Superluminal using its unique predict-design-test architecture. In addition, the two companies collaborated on predictive ADME modeling, resulting in models that both companies can use as needed for their respective business purposes. Building on this foundation, the new project will combine Axcelead DDP's comprehensive drug discovery platform, including its pharma-originated research data, rich experienced medicinal chemistry, and in vitro/in vivo pharmacology, with Superluminal's cutting-edge computational, AI/ML, and structure-based drug design capabilities. The collaboration aims to accelerate the discovery and development of innovative small-molecule therapeutics by jointly addressing multiple defined molecular targets with high unmet medical needs. "At Axcelead DDP, we have advanced our drug discovery platform, originally inherited from a top-tier pharmaceutical company, mainly through our own research, while strategically collaborating with external partners," said Kengo Okada, Ph.D., Representative Director and CEO of Axcelead DDP. "By applying this platform to support and accelerate Superluminal's drug discovery efforts targeting multiple mechanisms, we aim to contribute to the advancement of their pipeline and help address areas of high therapeutic demand. Our vision is to remain the drug discovery solution provider of choice for a diverse range of innovation-driven partners." Cony D'Cruz, CEO of Superluminal, added, "We are pleased with our partnership with Axcelead DDP. We appreciate the deep pharma experience and broad range of capabilities that enable Axcelead DDP to provide comprehensive drug discovery support to companies such as Superluminal." About Axcelead DDP Axcelead DDP is Japan's first drug discovery solution provider, established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions with original compound library and large drug discovery database are integrated into one center with a state-of-the-art research base. Together with experienced drug discovery scientists, Axcelead DDP creates high-quality drug candidates rapidly. By leveraging these strengths, Axcelead DDP provides solutions to various challenges faced in the process, from exploratory research to clinical trials in drug discovery. For more information, please visit About Superluminal Superluminal's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company's proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors, including RA Capital, Insight Partners, NVIDIA, Catalio Capital, Eli Lilly and Company, and Gaingels. For more, visit View source version on Contacts Axcelead Drug Discovery Partners, Superluminal Medicines, McCargo 6 Degreesjmccargo@
NHK
13-06-2025
- NHK
Japanese coastal cities Fujisawa, Kamakura saw rise in tourists in 2024
An increasing number of tourists visited two cities near Tokyo that are famous for their sightseeing spots and beaches last year. Officials from Fujisawa City say it welcomed an estimated 20.4 million travelers in 2024. That is up about 4 percent from the previous year and the highest since comparable data became available in 1989. The officials point to good weather during the summer when many people visit the beaches for bathing. They also say foreigners flocked to Enoshima Island, which offers views of the Pacific Ocean and Mount Fuji. Visitors spent a total of 113.8 billion yen, or nearly 800 million dollars, including accommodation fees and spending on food and drink. That is also a record. Officials from neighboring Kamakura City, known for its temples and shrines, say that the number of travelers surged about 30 percent year-on-year to 15.9 million. They attribute this to a rise in foreign tourists. Officials from the two cities say that they will promote tourism while protecting the quality of locals' daily lives. Both Fujisawa and Kamakura are about an hour's train ride from Tokyo.
The Drive
28-05-2025
- Automotive
- The Drive
Go From Wake Up to Wind Down With This Japanese Truck Factory Worker
The latest car news, reviews, and features. When I was a kid, my elementary school had a program that let students shadow adults at their job for a day. The idea was to show us what working as, say, an architect was like. 'Japanese assembly plant worker' wasn't one of the options available, but a video posted on YouTube fills that void. It documents a day in the life of someone who works in a huge Isuzu factory that assembles about 500 trucks per day. The video follows a 27-year-old man named Shun who lives in an apartment owned by Isuzu. This practice is fairly common in Japan: About 41% of Japanese companies offer some type of housing, according to the narrator. After getting ready, Shun walks 25 minutes to the Isuzu plant in Fujisawa, makes a quick stop at a 7-Eleven for breakfast, clocks in, and starts his shift as a manufacturing department captain. Beyond shedding light on the daily routine of a Japanese factory worker, the video gives us a fascinating and rarely seen glimpse at what an Isuzu plant looks like from the inside. About 6,000 people work in the Fujisawa plant, and it's so big that employees rely on shuttles to get around. And yet, every section of the factory that's shown in the video is stunningly clean. The narrator explains that this cleanliness is rooted in the Japanese concept of 'sort, set in order, and shine.' The idea is that a well-organized work environment increases productivity. Another thing that stands out in the video is the number of humans working on the assembly line. Isuzu builds commercial vehicles, not niche, small-batch supercars, so payload capacity and maintenance costs are more important to buyers than old-school craftsmanship. However, human workers remain essential because there are so many different variations of Isuzu's trucks all built under the same roof. The company notably sells different models, several variants of each model, as well as gasoline- and diesel-powered trucks. Workers like Shun keep the line moving smoothly and ensure that Isuzu can build a complete truck from start to finish in approximately 150 minutes. Got tips? Send 'em to tips@
